Skip to main content
Monday, November 16, 2026Nov 16

Science, patients driving rare disease drug research surge

In this Feb. 21, 2015 photo, Cara O'Neill, left, gives a kiss to her daughter, Eliza, 5, at their home in Columbia, S.C. Glenn and Cara O'Neill started the Cure Sanfilippo Foundation in hopes of saving Eliza, who suffers from the rare disease and is beginning to lose her ability to speak. The disease kills brain cells, causing hyperactivity and autistic-like behavior, then seizures, loss of ability to walk and usually death by the mid-teens. "The next six or seven years will be horrible for her, and then she'll die," her father said. (AP Photo/Rainier Ehrhardt)
In this Feb. 21, 2015 photo, Cara O'Neill, left, gives a kiss to her daughter, Eliza, 5, at their home in Columbia, S.C. Glenn and Cara O'Neill started the Cure Sanfilippo Foundation in hopes of saving Eliza, who suffers from the rare disease and is beginning to lose her ability to speak. The disease kills brain cells, causing hyperactivity and autistic-like behavior, then seizures, loss of ability to walk and usually death by the mid-teens. "The next six or seven years will be horrible for her, and then she'll die," her father said. (AP Photo/Rainier Ehrhardt)

TRENTON, N.J. (AP) – The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era of innovative therapies and big profits.

The investments come as researchers harness recent scientific advances, including the mapping of the human genome, sophisticated and affordable genetic tests and laboratory robots that can screen thousands of compounds per hour in search of the most potent ones.

“It’s a very, very promising time,” said Jimmy Lin, a National Institutes of Health cancer researcher who co-founded the Rare Genomics Institute.

By definition, a rare disease is one that strikes fewer than 200,000 Americans, sometimes only a few dozen. But with 7,000 rare diseases known to doctors, and more emerging all the time, nearly 1 in 10 Americans has a rare disease. For most, there is no treatment, let alone a cure. Just getting an accurate diagnosis often requires a medical odyssey, and 30 percent of children with a rare disease die before age 5.

For decades, drugmakers were reluctant to invest in rare-disease treatments, preferring to focus on mass-market drugs for cholesterol, heart trouble and other common problems. Then, starting a decade ago, patents on some of the industry’s most lucrative medicines began to expire, and cheap generic drugs started wiping out tens of billions of dollars in annual revenue.